Technetium-99m generators

Technetium-99m is a radio­active tracer that is used in twenty million medical dia­gnostic pro­ced­ures per year. At least 31 radio­phar­ma­ceut­icals based on Tc-99m are used for imaging and studying organs such as the brain, heart muscle, thyroid, lungs, liver, gall­bladder and kidneys, as well as the skeleton and blood and for the invest­ig­a­tion of tumours.

The ‘m’ in the name of technetium-99m indic­ates that it is meta­stable. Tc-99m is radio­active because one or more of the protons and neutrons in its nucleus is in an excited state. Tc-99m decays into Tc-99 with a half-life of six hours and this makes it par­tic­u­larly well suited to use in the body: after one day (four half-lives) only 6.3% of the initial Tc-99m remains. (It’s worth noting that the non-metastable technetium-99 is also radio­active, but with a half-life of 211000 years, it presents a very low risk.)

This short half-life also creates a problem: obtaining Tc-99m when required. Hos­pitals cannot run their own nuclear reactors and so they rely on tech­ne­tium gen­er­ators - machines that produce Tc-99m from the decay of its parent isotope molybdenum-99. Molybdenum-99 has a longer half-life (66 hours) and can there­fore be trans­ported to hos­pitals and still remain useful for up to a week.

Molybdenum-99 is produced in nuclear reactors by bom­barding a highly enriched uranium target with neutrons, causing it to fission, forming Mo-99 (and many other isotopes) as it does. The vast majority of Mo-99 is produced by five nuclear reactors around the world that are spe­cific­ally devoted to the pro­duc­tion of nuclear isotopes for medicine: NRU in Canada, BR2 in Belgium, SAFARI-1 in South Africa, HFR Petten in the Neth­er­lands and OSIRIS-1 in France.* Tem­porary shut­downs of NRU and HFR Petten in the 2000s led to a long-term shortage of Mo-99.

Once Mo-99 has been produced it is placed into a tech­ne­tium gen­er­ator and these gen­er­ators are trans­ported to hos­pitals. The tech­ne­tium gen­er­ators make use of the fact that molyb­denum likes to bond with alu­minium oxide (alumina) but tech­ne­tium does not. The gen­er­ators are “milked” by drawing a saline solution across an inner molybdenum/alumina capsule; during this elution process any tech­ne­tium that has formed will be drawn away with the saline and can then be used in tests.

A cutaway model of a tech­ne­tium generator.

The molybdenum/alumina sample is placed in the centre of the device, sur­rounded by shielding (painted red in this case). Saline is injected through one of the tubes at the top of the device and flows into a shielded con­tainer through the other tube, after having passed over the sample and “picked up” radio­active technetium-99m.

* Mo-99 is also produced in much smaller amounts from low-enriched uranium at the OPAL reactor in Aus­tralia and at other sites.

This entry was posted in General and tagged , . Bookmark the permalink.

2 Responses to Technetium-99m generators

  1. Will says:

    Fas­cin­ating post. I really enjoyed this one. A few question though, when the molybdenum/alumina capsule is milked with saline solution, why does the tech­ne­tium come out in the solution? Why is a saline solution used vs pure water? and finally: does the tech­ne­tium form a salt?

    Cheers.

  2. Mr Reid says:

    Saline is used because it can then be injected into a person; if you inject water into a vein it will cause hemo­lysis and possibly death. The reason tech­ne­tium comes out in solution is that tech­ne­tium does not bond to the alu­minium oxide like the molyb­denum does — it’s a form of chro­ma­to­graphy called “column chro­ma­to­graphy”.

Leave a Reply

Your email address will not be published.

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>